In nondiabetic CKD rats, chronic SGLT2i treatment activated neither intrarenal RAS, as determined by measuring the renal parenchyma angiotensin II concentration, nor systemic RAS, as reflected by the change in plasma RAS parameters such as renin activity and the angiotensinogen concentration [33]. This evidence concerns the gene AGT and chronic kidney disease.